M-RB1 - Supportive Oncology Technology

M-RB1 - Supportive Oncology Technology

Palliative Care

Information

M-RB1 is ASAlaser’s innovative robotic MLS® system, specifically designed to support oncology therapies with precision, safety, and reproducibility. By delivering hands-free, uniform laser treatment, R-B1 minimizes human error, optimizes session times, and ensures consistent therapeutic outcomes. Equipped with pre-set, clinically validated protocols developed over 10 years of research, the system can be fully personalized to meet each patient’s needs. R-B1 is designed to provide a comfortable, non-invasive, and effective care experience, improving quality of life during challenging cancer treatments. ASAlaser is the first company to receive EU MDR validation for five oncology-focused protocols: Acute Radiation Dermatitis (ARD) Oral Mucositis (RIOM) Hand-Foot Syndrome (HFS) Peripheral Neuropathy (CIPN) Myalgia/Contracture R-B1 represents the next generation of supportive oncology technology, combining robotic precision with evidence-based laser therapy to enhance patient care and clinical efficiency.
ASA S.r.l.S19.H111ASAlaser is an Italian company recognized worldwide for its excellence in the design and manufacture of advanced laser and magnetotherapy systems for medical and rehabilitative use. Founded in 1983, ASA quickly established itself as an international leader in the development of medical devices for both human and veterinary applications. Thanks to the combination of scientific research and technological innovation, ASAlaser develops effective, non-invasive systems for the treatment of painful and inflammatory conditions. Its flagship solution, MLS® Laser Therapy, is distinguished by a patented technology based on the combined and synchronized emission of continuous and pulsed wavelengths. Alongside this, Magnetotherapy Qs represents a traditional therapy that has been innovated and continuously updated by ASA to meet modern clinical needs. Since 2003, through its partnership with the El.En. Group, ASAlaser has expanded its portfolio to include Hilterapia®, a high-intensity laser therapy line with unique features unmatched by other therapeutic lasers, further strengthening the company’s comprehensive therapeutic offering. With over 40 years of experience, ASAlaser continues to invest in research, clinical validation, and compliance with international regulatory standards, supporting healthcare professionals worldwide in delivering safe, effective, and evidence-based therapies across rehabilitation, pain management, and supportive oncology.

Log in

See all the content and easy-to-use features by logging in or registering!